Lilly's Jaypirca approved as first-line CLL therapy

FDA approves Lilly's Jaypirca as first-line CLL therapy

The FDA approved pirtobrutinib (Jaypirca, Eli Lilly) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.